JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

Citi analyst Geoff Meacham lowered the firm’s price target on AbbVie (ABBV) to $215 from $226 and keeps a Buy rating on the shares. The ...

Are you a print subscriber? Activate your account. By Adrianne Pasquarelli - 2 hours 3 min ago By Erika Wheless - 2 hours 3 min ago By Brian Bonilla - 2 hours 3 min ago By Tim Nudd - 2 hours 3 min ...

(Reuters) - U.S. drugmaker AbbVie said on Monday it would acquire Aliada Therapeutics for $1.4 billion in cash, gaining access to the therapy developer's Alzheimer's disease drug candidate.

AbbVie is strengthening its neurology portfolio with a $1.4 billion acquisition of Aliada Therapeutics. The North Chicago-based drugmaker said in a statement this morning that Aliada has a blood ...

AbbVie (NYSE:ABBV) said Botox Cosmetic, added with its $63B acquisition of Allergan in 2020, is the first and only product ...

No significant news for ABBV in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...

AbbVie bumped earnings guidance higher following strong third-quarter sales as gains from the company's newer anti-inflammatory drugs offset expected declines from its former top dog, Humira. The ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct. 15th. While investors will wait to hear about quarterly earnings on ...

AbbVie Inc. said Thursday the Food and Drug Administration has approved its vyalev as the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of ...